secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001401914-22-000085
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Daré Q3 cash $40.4M; Ovaprene IDE approved; DARE-HRT1 positive efficacy data
----------------------------------------------------------------------------

- Cash $40.4M at Sep 30, 2022 vs $51.7M Dec 31, 2021; R&D expense $4.5M (down from $10.4M).
- FDA approved IDE for Ovaprene pivotal Phase 3 contraceptive study; investigator meeting Dec 2022.
- Positive topline efficacy data from DARE-HRT1 Phase 1/2 study; PK data expected later Q4 2022.
- Sildenafil Cream 3.6% Phase 2b RESPOND subject screening completed; topline data targeted Q2 2023.
- XACIATO first commercial sale expected 1H 2023 under Organon license agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000140191422000085/0001401914-22-000085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000140191422000085/dare-20221110.htm
  HTML page:      https://secwatch.observer/filing/0001401914-22-000085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer